Shares of GlaxoSmithKline PLC (NYSE:GSK) have been given an average recommendation of “Hold” by the twenty-two ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $45.67.
Several research firms have issued reports on GSK. Citigroup Inc. restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 27th. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, May 31st. TheStreet cut shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 target price on the stock in a research note on Tuesday, July 18th. Finally, Berenberg Bank upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research note on Friday, May 26th.
COPYRIGHT VIOLATION NOTICE: This article was first posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/glaxosmithkline-plc-gsk-given-consensus-rating-of-hold-by-analysts-updated.html.
GlaxoSmithKline PLC (GSK) traded down 0.37% during mid-day trading on Tuesday, reaching $40.15. 2,272,250 shares of the company were exchanged. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $44.59. The company has a market capitalization of $98.13 billion, a PE ratio of 39.60 and a beta of 1.03. The stock has a 50-day moving average price of $42.44 and a 200 day moving average price of $41.81.
GlaxoSmithKline PLC (NYSE:GSK) last posted its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Analysts predict that GlaxoSmithKline PLC will post $2.85 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a $0.491 dividend. This represents a $1.96 annualized dividend and a yield of 4.89%. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio is currently 194.00%.
A number of large investors have recently added to or reduced their stakes in the company. Capstone Asset Management Co. raised its stake in GlaxoSmithKline PLC by 6.7% in the first quarter. Capstone Asset Management Co. now owns 102,668 shares of the pharmaceutical company’s stock valued at $4,328,000 after buying an additional 6,420 shares in the last quarter. Jacobs & Co. CA raised its stake in GlaxoSmithKline PLC by 5.6% in the first quarter. Jacobs & Co. CA now owns 80,093 shares of the pharmaceutical company’s stock valued at $3,376,000 after buying an additional 4,270 shares in the last quarter. Regentatlantic Capital LLC purchased a new stake in GlaxoSmithKline PLC during the first quarter valued at about $268,000. Bank of Montreal Can raised its stake in GlaxoSmithKline PLC by 8.8% in the first quarter. Bank of Montreal Can now owns 128,238 shares of the pharmaceutical company’s stock valued at $5,407,000 after buying an additional 10,412 shares in the last quarter. Finally, Highland Capital Management LLC raised its stake in GlaxoSmithKline PLC by 13.7% in the first quarter. Highland Capital Management LLC now owns 79,249 shares of the pharmaceutical company’s stock valued at $3,341,000 after buying an additional 9,520 shares in the last quarter. 8.96% of the stock is owned by institutional investors.
GlaxoSmithKline PLC Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.